Vascular Targets for the Treatment of Portal Hypertension
The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Abstract
Portal hypertension is the main driver for severe complications in patients with liver cirrhosis. With improved understanding of molecular pathways that promote hepatic vascular remodeling, vasoconstriction, and sinusoidal capillarization potential vascular targets for the treatment of portal hypertension have been identified. Inhibition of vascular endothelial and platelet-derived growth factors–driven angiogenesis has been shown to reduce portal pressure and decrease hepatic inflammation. Angiopoietin/Tie signaling represents additional promising vascular targets in liver disease. The eNOS-NO-sGC-cGMP pathway modulates sinusoidal vasoconstriction and capillarization. Nuclear farnesoid X receptor (FXR) agonists decrease intrahepatic vascular resistance by inhibition of fibrogenesis and sinusoidal remodeling. Statins ameliorate endothelial dysfunction, decrease portal pressure, and reduce fibrogenesis. Anticoagulation with low-molecular heparin or anti-Xa inhibitors improved portal hypertension by deactivation of hepatic stellate cells and potentially via reduction of sinusoidal microthrombosis. This review summarizes important vascular targets for treatment of portal hypertension that have shown promising results in experimental studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cilofexor was associated with a decrease in portal hypertension (what highlights FXR also as a vascular target [90]), reduced liver fibrosis in NASH rats and decreased mesenteric hyperperfusion in combination with propranolol.[70]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [90]
Citations
Cites
Vu, T.-K. H., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991) · Cell · doi:10.1016/0092-8674(91)90261-v · Cited by 2,970
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
The Role of Oxidative Stress and Antioxidants in Liver Diseases
Li, S., Tan, H.-Y., Wang, N., Zhang, Z.-J., Lao, L., Wong, C.-W., & Feng, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125942 · Cited by 1,835
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Oxidative stress as a crucial factor in liver diseases
Cichoż-Lach, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i25.8082 · Cited by 1,216
Inflammation, immunoregulation, and inducible nitric oxide synthase
Nussler, A. K., & Billiar, T. R. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.54.2.171 · Cited by 860
Hernández-Perera, O., Pérez-Sala, D., Navarro-Antolín, J., Sánchez-Pascuala, R., Hernández, G., Díaz, C., & Lamas, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1500 · Cited by 763
Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., Schmidt, H. H. H. W., & Stasch, J.-P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2038 · Cited by 749
Cited by
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
“I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
BackgroundLiver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma
Li, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1842732 · Cited by 79
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 85
“With the progression of NAFLD, sustained IHVR promotes vasodilation in splanchnic and systemic arteries, resulting in decreased systemic vascular resistance and eventually in the development of spontaneous portosystemic shunts [100].”
BackgroundInfluentialLi, H. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.006 · Cited by 51
Metadata
- Authors
- Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Reiberger, Thomas
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2019-07-17
- Volume
- 39
- Issue
- 04
- Pages
- 483-501
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2956285561
- Cited by
- 28
- References
- 257
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 3
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- portal hypertension, liver cirrhosis, angiogenesis, vascular endothelial growth factor, platelet-derived growth factor, nitric oxide signaling, endothelial nitric oxide synthase, statins, endothelial dysfunction, liver fibrosis, low molecular weight heparin, anti-Xa inhibitors, hepatic stellate cells, sinusoidal capillarization, vasoconstriction
- MeSH terms
- Soluble Guanylyl Cyclase, Receptor, Farnesoid X-Activated, Anticoagulants, Cyclic GMP, Humans, Hypertension, Portal, Neovascularization, Pathologic, Nitric Oxide, Receptors, Cytoplasmic and Nuclear, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular Targets for the Treatment of Portal Hypertension. https://app.cochat.ai/papers/10.1055/s-0039-1693115
- The paper
- Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019). Vascular Targets for the Treatment of Portal Hypertension. Seminars in Liver Disease. https://doi.org/10.1055/s-0039-1693115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.